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annual health care costs (P < 0.01) compared to patients start-
ing other oral antidiabetic agents. CONCLUSIONS: Introduc-
tion of thiazolidinedione therapy in a Medicaid-enrolled type 2
diabetic population was associated with signiﬁcantly greater
treatment persistence and lower healthcare costs in the post-start
year compared to patients starting other oral antidiabetic agents.
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OBJECTIVE: To assess the economic impact of augmentation
therapy [thiazolidinediones (TZDs) or metformin] in type 2 dia-
betes patients who initiated mono-therapy with sulfonylurea.
METHODS: A retrospective cohort design was used to meet the
study objective. Patients newly diagnosed with type 2 diabetes
and initiating therapy with sulfonylurea were identiﬁed during
the four-year period (1998–2001) from a Medicaid claims data-
base. These patients were then followed till they augmented
therapy by adding another oral hypoglycemic agent (TZDs or
metformin) to their regimen. The date of the ﬁrst prescription
for a TZD or metformin was treated as the index date and type
2 diabetes-related costs in the 12-month follow-up period were
assessed. Semi-logarithmic OLS models were used to estimate the
impact of therapy on total diabetes-related costs. Costs were also
examined separately in terms of diabetes-related Emergency
Room (ER)/hospitalization, outpatient and prescription costs
using appropriate two-part models. RESULTS: The ﬁnal cohort
consisted of 298 type 2 diabetes patients who initiated mono-
therapy with sulfonylureas and augmented with either TZDs (n
= 96) or metformin (n = 202). Results of the semi-log OLS model
indicated that patients augmenting sulfonylurea therapy with
metformin incurred 33.27% lower total diabetes-related costs as
compared to those augmenting therapy with TZDs (p < 0.001).
Further breakdown of the costs indicated that there were no sig-
niﬁcant differences in diabetes-related ER/Hospitalization and
outpatient costs between the two groups. However, diabetes-
related prescription costs were 45.47% lower for patients aug-
menting with metformin as compared those augmenting with
TZDs (p < 0.001). CONCLUSION: Patients with type 2 diabetes
initiated on mono-therapy with sulfonylureas and augmenting
with metformin have signiﬁcantly lower type 2 diabetes-related
costs as compared to those augmenting with TZDs, primarily
due to lower prescription costs. The study results can aid in
making important formulary decisions and developing treatment
algorithms for management of type 2 diabetes.
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OBJECTIVES: To determine the cost-effectiveness of adding
angiotensin-converting enzyme inhibitor (ACEI) therapy at
normo-, micro-, and macro-albuminuric stages in Type II dia-
betics. METHODS: We employed a recently published Markov
model depicting nephropathy and cardiovascular disease (CVD)
events among diabetics. Probabilities and costs were from the 
literature. We incorporated a health payer perspective, direct
medical costs with 3% discounting, 1 year cycles, and a 6 year
time horizon. Endpoints were cost/life-year gained (LYG),
cost/death avoided, cost/CVD event averted, cost/patient pre-
vented from dialysis, and cost/composite endpoint (death, CVD
event, dialysis) averted. End-stage renal disease (ESRD) was
excluded from baseline; we assumed these patients would
already be on ACEIs unless contraindicated. We used informa-
tion from the New Mexico Medicaid diabetic population to
ascertain prevalence of each stage of nephropathy and mean age
(68.8 years). The base case included the average cost for ACEIs
at target doses. RESULTS: ACEI treatment is dominant when
initiated in normoalbuminuric patients. Starting ACEI therapy
at microalbuminuria provides incremental cost-effectiveness
ratios (ICERs) of $624.21, $28,000.43, $129.85, and $13.21 per
avoidance of CVD event, dialysis event, death, and LYG, respec-
tively. Waiting until macroalbuminuria causes ACEI therapy to
be dominated for CVD and dialysis events due to lower survival
with the no ACEI alternative. ICERs for death and LYG are
$431.28 and $43.87, respectively. In one-way sensitivity analy-
ses the model was sensitive to ACEI costs and insensitive to dial-
ysis costs. For two-way sensitivity analyses we incorporated
ACEI and dialysis costs and assumed ACEIs further attenuate
the progression from macroalbuminuria to ESRD by 20%.
Across all stages of nephropathy for each cost variation, cost per
additional dialysis event avoided was most impacted in this
analysis. CONCLUSIONS: In most patients, ACEIs should be
initiated upon diagnosis of Type II diabetes to prevent higher
healthcare costs due to more events in the future.
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The increased costs of intensive early management of diabetes
may be offset by a reduction in future complications. As com-
plications of diabetes have been shown to signiﬁcantly contribute
to health care costs, computer simulation models are increasingly
being used to evaluate the likely impact of interventions on the
progression of diabetes as well as the health and economic con-
sequences interventions are likely to accrue over a patient’s life-
time. OBJECTIVES: Stimulate long-term costs and consequences
of an observational 18-month nurse-led multifaceted diabetes
management program aimed at the patient, the health care
providers and the health care system. METHODS: We con-
ducted a cost-effectiveness analysis based on patient-level data
from an observational study involving 404 patients with dia-
betes. Changes in intermediate outcomes (e.g. HbA1c, blood
pressure, cholesterol, and smoking status) at the end of the inter-
vention period were measured and used as risk factors in a Cana-
dian-speciﬁc probabilistic discrete-event model to simulate the
mean difference in cost and expected quality-adjusted life years
(QALYs). Incremental cost-effectiveness ratios were calculated
based on the net cost of health care resources associated with the
program and on effectiveness estimated over a patient’s lifetime.
In the base case, the cost-effectiveness ratio was calculated
assuming the effect of the intervention continued for 1 year using
a discount rate of 3%. RESULTS: The multifaceted diabetes
management program on average reduced HbA1c by 1% (SD
2.3%), systolic blood pressure by 1.4mmHg (SD 21.3), total to
HDL cholesterol ratio by 0.69 (SD 1.30). The incremental cost
